Table 1 Baseline characteristics
Treatment assignment | ||
|---|---|---|
Characteristic, n (%) | Apatorsen and docetaxel (n = 99) | Docetaxel (n = 101) |
Age, median years (range) | 68 (43–90) | 67 (35–92) |
Sex | ||
Male | 74 (74.7%) | 75 (74.3%) |
Female | 25 (25.3%) | 26 (25.6%) |
Race | ||
Caucasian | 89 (89.9%) | 92 (91.1%) |
African American | 3 (3%) | 4 (4%) |
Asian | 5 (5.1%) | 3 (3%) |
Unknown | 2 (2%) | 2 (2%) |
ECOG performance statusa | ||
0 | 43 (43.4%) | 41 (40.6%) |
1 | 56 (56.6%) | 59 (58.4%) |
Urothelial carcinoma (at study entry) | ||
Metastatic | 85 (85.9%) | 87 (86.1%) |
Locally advanced | 6 (6.1%) | 10 (9.9%) |
Unknown | 8 (8.1%) | 4 (4%) |
Primary surgery | ||
Yes | 40 (40.4%) | 36 (35.6%) |
Prior cisplatin use | ||
Yes | 70 (70.7%) | 72 (71.3%) |
Prior carboplatin use | ||
Yes | 38 (38.4%) | 41 (40.6%) |
Primary disease site(s) | ||
Bladder | 64 (64.6%) | 72 (71.3%) |
Renal pelvis | 27 (27.3%) | 13 (12.9%) |
Ureter | 13 (13.1%) | 14 (13.9%) |
Urethra | 7 (7.1%) | 9 (8.9%) |
Metastatic sites | ||
Liver | 28 (28.3%) | 25 (24.8%) |
Lung | 34 (34.3%) | 35 (34.7%) |
Bone | 19 (19.2%) | 21 (20.8%) |
Lymph nodes | 56 (56.6%) | 52 (51.5%) |
Bellmunt prognostic factorsb | ||
0 | 27 (27.3%) | 32 (31.7%) |
1 | 42 (42.4%) | 35 (34.7%) |
2 | 23 (23.2%) | 26 (25.7%) |
3 | 7 (7.1%) | 7 (6.9%) |
